|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amgen's eventful earnings Thursday afternoon shared some new updates on its battle with the FDA over the fate of Tavneos, revealed a cut to a mid-stage cancer program and set up trials that test MariTide directly with the GLP-1 competition. Amgen's stock dropped 6% on the results by midday Friday. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Nicole DeFeudis
|
Amgen is launching three new late-stage trials for its long-acting obesity shot MariTide, including one designed to test the drug in patients switching away from... | |
|
|
|
 |
|
Credit: Seaport Therapeutics |
|
|
|
by Max Gelman
|
Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose SPTX more than 20%. With a... | |
|
|
|
|
|
|
by Max Gelman
|
The FDA on Friday approvedPfizer and Arvinas' drug vepdegestrant for patients with a certain form of breast cancer. But it’s unclear how many will... | |
|
|
|
|
|
|
by Max Bayer
|
Moderna said it's working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after... | |
|
|
|
|
|
|
|
|
by Anna Brown
|
After holding a rally in April, Samsung Biologics union workers on Friday started a five-day strike over wage negotiations. Around 95% of the company's
union... | |
|
|
|
|
|